From The Editor | August 28, 2014

Patheon Surfs Outsourcing Waves And Scoops Up Gallus Along The Way

To access this content, please Register or Sign In.

By Louis Garguilo, Executive Editor, Outsourced Pharma
Follow Me On Twitter @Louis_Garguilo

Louis

Jim Mullen, CEO of Patheon parent company DPx Holdings B.V., is at it again.

On the heels of Outsourced Pharma’s three-part series with Mullen on the details behind the springtime merger of his company and the pharmaceutical products division of Royal DSM, he has made his next move.

This time it is a strategic entrée into the U.S.-based market for biologics services via an acquisition of privately held Gallus BioPharmaceuticals. With Gallus, Patheon adds new capabilities at well-established sites with name-brand clientele, in St. Louis, Mo. and Princeton, N.J., to its global locations in Groningen, the Netherlands and Brisbane, Australia.